IntegraGen SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0010908723
EUR
0.14
0 (-2.44%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 1 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.30

stock-summary
Return on Equity

-154.73%

stock-summary
Price to Book

1.11

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-51.72%
0%
-51.72%
6 Months
-73.38%
0%
-73.38%
1 Year
-74.07%
0%
-74.07%
2 Years
-84.44%
0%
-84.44%
3 Years
-88.24%
0%
-88.24%
4 Years
-87.63%
0%
-87.63%
5 Years
-93.4%
0%
-93.4%

IntegraGen SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-5.38%
EBIT Growth (5y)
-203.01%
EBIT to Interest (avg)
-0.37
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.72
Sales to Capital Employed (avg)
4.43
Tax Ratio
9.65%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.58
EV to EBIT
0.25
EV to EBITDA
0.25
EV to Capital Employed
-0.25
EV to Sales
-0.03
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-14.60%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by IntegraGen SA"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is -5.30% vs 16.81% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "12.50",
          "val2": "13.20",
          "chgp": "-5.30%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.20",
          "val2": "0.10",
          "chgp": "-300.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.20",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-32.50%",
          "val2": "-8.30%",
          "chgp": "-2.42%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
12.50
13.20
-5.30%
Operating Profit (PBDIT) excl Other Income
-0.20
0.10
-300.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.20
-0.00
Operating Profit Margin (Excl OI)
-32.50%
-8.30%
-2.42%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is -5.30% vs 16.81% in Dec 2022

Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022

stock-summaryCompany CV
About IntegraGen SA stock-summary
stock-summary
IntegraGen SA
Pharmaceuticals & Biotechnology
Integragen SA is a France-based company active in the healthcare sector. It researches and develops biomarkers for use as diagnostic tools in the fields of autism, oncology, diabetes and obesity. It uses an evaluation model with several autism-related genes using a combination of several common polymorphisms (Single-Nucleotide Polymorphism or SNP or common variant). It also develops molecular biomarker validation programs for Hepatocellular Carcinoma and anti-epidermal growth factor receptor (anti-EGFR) resistance markers. The Company also provides genomics services to practitioners and researchers, such as DNA extraction, marker selection and tagging and bioinformatical analysis of sequence data in such fields as pharmacogenetics, cytogenetics, epigenetics, search for mutations and SNP discovery, among others. As of December 31, 2011, the Company operated through a wholly owned subsidiary, IntegraGen Inc.
Company Coordinates stock-summary
Company Details
Genopole Campus 1, Genavenir 8 5 rue Henri Desbrueres EVRY None : 91000
stock-summary
Tel: 33 1 60910900
stock-summary
Registrar Details